Ruei-Zeng Lin, PhD

Ruei-Zeng Lin, PhD has a strong background in cell engineering and therapy, with extensive experience in both research and project management roles. They have worked at several prestigious institutions including Harvard Medical School and Boston Children's Hospital. At Harvard Medical School, they served as a Scientist and Project Leader, leading multi-disciplinary teams and specializing in cardiovascular and innate immunology in the field of cell and gene therapy. During their time there, they published 40 papers, including publications in Nature Biomedical Engineering, PNAS, and Blood.

Prior to Harvard Medical School, Ruei-Zeng Lin worked as an Instructor at Harvard Medical School, leading a research team and executing multiple projects in cell-based therapies for various diseases. They have also been involved in patentable technology development, with 2 US patents and 3 invention discourses in progress. Additionally, they have contributed to the establishment of technical SOPs used in multiple laboratories nationwide.

Before their role as an Instructor, Ruei-Zeng Lin was a Postdoctoral Researcher at Harvard Medical School, where they gained extensive hands-on research experience in cell therapy and cell engineering. They published 17 papers and played a key role in obtaining NIH-funded grants.

Ruei-Zeng Lin's career began at Boston Children's Hospital as a Research Fellow and later as a Staff Scientist and Principal Investigator. During their time there, they focused on genetically engineering vasculature for therapeutic protein delivery and developed techniques for efficient endothelial differentiation from human iPSCs.

Currently, Ruei-Zeng Lin is working as a Principal Scientist in Cell Engineering at Myeloid Therapeutics.

Ruei-Zeng Lin, PhD, obtained a Bachelor of Engineering degree in Material Science and Engineering with a minor in Life Science from National Tsing Hua University in 2002. Following this, they pursued a Doctor of Philosophy degree in Molecular Medicine at the same institution, completing their Ph.D. studies in 2007.